Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Medtronic
Harvard Business School
Mallinckrodt

Last Updated: February 3, 2023

Casimersen - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for casimersen and what is the scope of patent protection?

Casimersen is the generic ingredient in one branded drug marketed by Sarepta Theraps Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Casimersen has seventy-eight patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for casimersen
International Patents:78
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 3
What excipients (inactive ingredients) are in casimersen?casimersen excipients list
DailyMed Link:casimersen at DailyMed
Recent Clinical Trials for casimersen

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kevin FlaniganPhase 2
Sarepta Therapeutics, Inc.Phase 2
Sarepta Therapeutics, Inc.Phase 3

See all casimersen clinical trials

Pharmacology for casimersen

US Patents and Regulatory Information for casimersen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for casimersen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 See Plans and Pricing See Plans and Pricing
Sarepta Theraps Inc AMONDYS 45 casimersen SOLUTION;INTRAVENOUS 213026-001 Feb 25, 2021 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for casimersen

Country Patent Number Title Estimated Expiration
Spain 2693459 See Plans and Pricing
South Korea 20210041130 See Plans and Pricing
Serbia 58079 See Plans and Pricing
New Zealand 626359 Antisense molecules and methods for treating pathologies See Plans and Pricing
Spain 2564185 See Plans and Pricing
Hong Kong 1245325 用於誘導外顯子跳躍的反義寡核苷酸及其使用方法 (ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Merck
Colorcon
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.